IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
David T. Rubin, MD
Michael Dolinger, MD, MBA
Florence Odufalu, MD
Ugo Iroku, MD, MHS
Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP
Revisiting Anti-TNFs: Role, Risks, and Real-World Considerations
Where Conventional IBD Therapies Fall Short
Small Molecules in IBD: JAK Inhibitors and S1P Modulators
The Future of Biologic Treatment in IBD: What’s on the Horizon
Setting the Stage: Why Rethinking IBD Care Matters Now
The Evolving Role of Small Molecules in IBD Care
Translating Advances into Practice: Lessons from Today’s IBD Landscape
Understanding the Microbiome’s Role in IBD Management
IBD Beyond Symptoms: What Community GIs Need to Know
Pathophysiology of IBD: The War Within
Severity Assessment: Can You Pin the Stage on the Patient?
Jennifer Geremia, PA-C
Brooke Hodnick, PA-C, MPAS
Case Review: Targets Are Met—Can You Stick the Landing?
David Rubin, MD
Treat-to-Target: Are We There Yet?
Kimberly D. Orleck, PA-C
Case Review: Can You Crack This IBD Case?
Tailoring Treatment: Can You Select the Best Therapy?
Loading...
We're glad to see you're enjoying Crohn's Colitis Professional… but how about a more personalized experience?
Press cancel to remain on Crohn's Colitis Professional. Press the link below or the continue button to keep going.